McKESSON CORPORATION FINANCIAL REVIEW (Continued) 36 Other Income, Net:
## Table 0 ##
In 2011, other income, net included the receipt of $16 million representing the reimbursement of postacquisition interest expense by the former shareholders of US Oncology, which is recorded in Corporate.
In 2010, other income, net included a $17 million pre-tax gain ($14 million after-tax) from the sale of our 50% equity interest in MLS.
The gain on sale of our investment in MLS was recorded within our Distribution Solutions segment.
Segment Operating Profit and Corporate Expenses:
## Table 1 ##
(1) Segment operating profit includes gross profit, net of operating expenses, plus other income, net for our two operating segments.
(2) Operating expenses for 2012 and 2011 for our Distribution Solutions segment included $149 million and $213 million of AWP litigation charges.
Operating profit margin for our Distribution Solutions segment increased in 2012 compared to 2011 primarily due to higher gross profit margin, which included a full year of results from US Oncology, and lower operating expenses as a percentage of revenues, which included a lower AWP litigation charge.
Operating profit margin for our Distribution Solutions segment decreased in 2011 compared to 2010 primarily due to higher operating expenses as a percentage of revenue, including a $213 million AWP litigation charge, partially offset by a higher gross profit margin, which included the receipt of $51 million representing our share of an antitrust class action lawsuit brought against a drug manufacturer.
Operating profit margin in our Technology Solutions segment increased in 2012 compared to 2011 primarily reflecting an increase in gross profit margin, partially offset by an increase in operating expenses as a percentage of revenues.
Operating profit margin in our Technology Solutions segment decreased in 2011 compared to 2010 primarily reflecting a decrease in gross profit margin, which included the $72 million asset impairment charge, and an increase in operating expenses as a percentage of revenues.
McKESSON CORPORATION FINANCIAL REVIEW (Continued) 46 In 2012 and 2011, the majority of our share repurchases were transacted through a number of ASR programs with third party financial institutions as follows: $1.0 billion in May 2010, $275 million in March 2011, $650 million in May 2011 and $1.2 billion in March 2012.
In 2010, all of our share repurchases were conducted through open market transactions.
All programs were funded with cash on hand.
In March 2012, we entered into an ASR program with a third party financial institution to repurchase $1.2 billion of the Company’s common stock.
As of March 31, 2012, we had received 12 million shares representing the minimum number of shares due under this program, and the average price paid per share of $87.19 was based on the average daily volume-weighted average price of our common stock less a discount calculated as of March 31, 2012.
The total number of shares to be ultimately repurchased by us and the final settlement price per share will be determined at the completion of this program based on the average daily volume-weighted average price of our common stock during the program, less a discount.
This program is anticipated to be completed no later than the second quarter of 2013.
In April 2012, the Board authorized the repurchase of an additional $700 million of the Company’s common stock, bringing the total authorization outstanding to $1.0 billion.
Although we believe that our operating cash flow, financial assets, current access to capital and credit markets, including our existing credit and sales facilities, will give us the ability to meet our financing needs for the foreseeable future, there can be no assurance that continued or increased volatility and disruption in the global capital and credit markets will not impair our liquidity or increase our costs of borrowing.
Selected Measures of Liquidity and Capital Resources:
## Table 2 ##
(1) Ratio is computed as total debt divided by the sum of total debt and stockholders’ equity.
(2) Ratio is computed as total debt, net of cash and cash equivalents (“net debt”), divided by the sum of net debt and stockholders’ equity (“net capital employed”).
(3) Ratio is computed as net income for the last four quarters, divided by a five-quarter average of stockholders’ equity.
Our cash and equivalents balance as of March 31, 2012 included approximately $1.4 billion of cash held by our subsidiaries outside of the United States.
Our primary intent is to utilize this cash in the foreign operations as well as to fund certain research and development activities for an indefinite period of time.
Although the vast majority of cash held outside the United States is available for repatriation, doing so could subject us to U. S.  federal, state and local income tax.
During the fourth quarter of 2011 and pursuant to IRS regulations, we temporarily borrowed and repaid $1.0 billion of cash held by our subsidiaries outside the United States.
The duration of this temporary loan to the United States was less than 60 days.
Working capital primarily includes cash and cash equivalents, receivables and inventories, net of drafts and accounts payable, deferred revenue and other current liabilities.
Our Distribution Solutions segment requires a substantial investment in working capital that is susceptible to large variations during the year as a result of inventory purchase patterns and seasonal demands.
Inventory purchase activity is a function of sales activity and other requirements.
McKESSON CORPORATION 3 PART I Item 1.  Business.
General McKesson Corporation (“McKesson,” the “Company,” the “Registrant” or “we” and other similar pronouns), is a Fortune 15 corporation that delivers pharmaceuticals, medical supplies and health care information technologies that make health care safer while reducing costs.
The Company’s fiscal year begins on April 1 and ends on March 31.
Unless otherwise noted, all references in this document to a particular year shall mean the Company’s fiscal year.
Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act,”) are available free of charge on our website (www.
mckesson.
com under the “Investors – Financial Information – SEC Filings” caption) as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission (“SEC” or the “Commission”).
The content on any website referred to in this Annual Report on Form 10-K is not incorporated by reference into this report, unless expressly noted otherwise.
The public may also read or copy any materials that we file with the SEC at the SEC’s Public Reference Room at 100 F Street, NE, Washington, D. C.  20549.
The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330.
The SEC maintains a website that contains reports, proxy and information statements, and other information regarding issuers, including the Company, that file electronically with the SEC.
The address of the website is http://www.
sec.
gov.
Business Segments We operate in two segments.
The McKesson Distribution Solutions segment distributes ethical and proprietary drugs, medical-surgical supplies and equipment and health and beauty care products throughout North America.
This segment also provides specialty pharmaceutical solutions for biotech and pharmaceutical manufacturers, and practice management, technology, clinical support and business solutions to oncology and other specialty practices operating in the community setting.
In addition, this segment sells financial, operational and clinical solutions for pharmacies (retail, hospital, alternate site) and provides consulting, outsourcing and other services.
This segment includes a 49% interest in Nadro, S. A.  de C. V.  (“Nadro”), one of the leading pharmaceutical distributors in Mexico.
The McKesson Technology Solutions segment delivers enterprise-wide clinical, patient care, financial, supply chain, strategic management software solutions, pharmacy automation for hospitals, as well as connectivity, outsourcing and other services, including remote hosting and managed services, to healthcare organizations.
This segment also includes our Payer group of businesses, which includes our InterQual?
clinical criteria solution, medical management tools, claims payment solutions, network performance tools and care management programs.
This segment’s customers include hospitals, physicians, homecare providers, retail pharmacies and payers from North America, the United Kingdom, Ireland, other European countries and Israel.
Net revenues for our segments for the last three years were as follows:
## Table 3 ##
Notes to the Consolidated Financial Statements (continued) During 2005, we amended our $1.0 billion unsecured revolving credit facility to extend its maturity date from March 27, 2008 to March 27, 2010, and reduce the effective interest rate to LIBOR plus 1.0% and the commitment fee to 0.2% of the undrawn portion of the facility at December 31, 2005.
In addition, in 2005, we entered into two $100.0 million unsecured term loans, due 2010, at an effective interest rate of LIBOR plus 0.8% at December 31, 2005.
During 2004, we entered into an eight-year, $225.0 million unsecured term loan, at LIBOR plus 1.75%, which was amended in 2005 to reduce the effective interest rate to LIBOR plus 1.0% at December 31, 2005.
The Liquid Yield Option?
Notes and the zero coupon convertible notes are unsecured zero coupon bonds with yields to maturity of 4.875% and 4.75%, respectively, due 2021.
Each Liquid Yield Option?
Note and zero coupon convertible note was issued at a price of $381.63 and $391.06, respectively, and will have a principal amount at maturity of $1,000.
Each Liquid Yield Option?
Note and zero coupon convertible note is convertible at the option of the holder into 11.7152 and 15.6675 shares of common stock, respectively, if the market price of our common stock reaches certain levels.
These conditions were met at December 31, 2005 and 2004 for the zero coupon convertible notes and at December 31, 2004 for the Liquid Yield Option?
Notes.
Since February 2, 2005, we have the right to redeem the Liquid Yield Option?
Notes and commencing on May 18, 2006, we will have the right to redeem the zero coupon convertible notes at their accreted values for cash as a whole at any time, or from time to time in part.
Holders may require us to purchase any outstanding Liquid Yield Option?
Notes at their accreted value on February 2, 2011 and any outstanding zero coupon convertible notes at their accreted value on May 18, 2009 and May 18, 2014.
We may choose to pay the purchase price in cash or common stock or a combination thereof.
During 2005, holders of our Liquid Yield Option?
Notes and zero coupon convertible notes converted approximately $10.4 million and $285.0 million, respectively, of the accreted value of these notes into approximately 0.3 million and 9.4 million shares, respectively, of our common stock and cash for fractional shares.
In addition, we called for redemption $182.3 million of the accreted balance of outstanding Liquid Yield Option?
Notes.
Most holders of the Liquid Yield Option?
Notes elected to convert into shares of our common stock, rather than redeem for cash, resulting in the issuance of approximately 4.5 million shares.
During 2005, we prepaid a total of $297.0 million on a term loan secured by a certain Celebrity ship and on a variable rate unsecured term loan.
In 1996, we entered into a $264.0 million capital lease to finance Splendour of the Seas and in 1995 we entered into a $260.0 million capital lease to finance Legend of the Seas.
During 2005, we paid $335.8 million in connection with the exercise of purchase options on these capital lease obligations.
Under certain of our agreements, the contractual interest rate and commitment fee vary with our debt rating.
The unsecured senior notes and senior debentures are not redeemable prior to maturity.
Our debt agreements contain covenants that require us, among other things, to maintain minimum net worth and fixed charge coverage ratio and limit our debt to capital ratio.
We are in compliance with all covenants as of December 31, 2005.
Following is a schedule of annual maturities on long-term debt as of December 31, 2005 for each of the next five years (in thousands):

<table><tr><td></td><td colspan="3"> Years Ended March 31,</td><td colspan="2"> Change</td></tr><tr><td><i>(Dollars in millions)</i></td><td> 2012</td><td> 2011</td><td> 2010</td><td> 2012</td><td> 2011</td></tr><tr><td>Other Income, Net</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Distribution Solutions</td><td>$16</td><td>$5</td><td>$29</td><td>220%</td><td>-83%</td></tr><tr><td>Technology Solutions</td><td>5</td><td>4</td><td>5</td><td>25</td><td>-20</td></tr><tr><td>Corporate</td><td>—</td><td>27</td><td>9</td><td>-100</td><td>200</td></tr><tr><td>Total</td><td>$21</td><td>$36</td><td>$43</td><td>-42</td><td>-16</td></tr></table>
<table><tr><td></td><td colspan="3"> Years Ended March 31,</td><td colspan="2"> Change</td></tr><tr><td><i>(Dollars in millions)</i></td><td> 2012</td><td> 2011</td><td> 2010</td><td> 2012</td><td> 2011</td></tr><tr><td>Segment Operating Profit<sup>-1</sup></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Distribution Solutions<sup>-2</sup></td><td>$2,219</td><td>$1,897</td><td>$1,988</td><td>17%</td><td>-5%</td></tr><tr><td>Technology Solutions</td><td>364</td><td>301</td><td>385</td><td>21</td><td>-22</td></tr><tr><td>Subtotal</td><td>2,583</td><td>2,198</td><td>2,373</td><td>18</td><td>-7</td></tr><tr><td>Corporate Expenses, Net</td><td>-413</td><td>-341</td><td>-342</td><td>21</td><td>—</td></tr><tr><td>Litigation Credit, Net</td><td>—</td><td>—</td><td>20</td><td>—</td><td>—</td></tr><tr><td>Interest Expense</td><td>-251</td><td>-222</td><td>-187</td><td>13</td><td>19</td></tr><tr><td>Income from Continuing Operations Before Income Taxes</td><td>$1,919</td><td>$1,635</td><td>$1,864</td><td>17</td><td>-12</td></tr><tr><td>Segment Operating Profit Margin</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Distribution Solutions</td><td>1.86%</td><td>1.74%</td><td>1.88%</td><td>12bp</td><td>-14bp</td></tr><tr><td>Technology Solutions</td><td>11.00</td><td>9.42</td><td>12.32</td><td>158</td><td>-290</td></tr></table>
<table><tr><td></td><td colspan="3"> March 31,</td></tr><tr><td> <i>(Dollars in millions)</i> </td><td> 2012</td><td> 2011</td><td> 2010</td></tr><tr><td>Cash and cash equivalents</td><td>$3,149</td><td>$3,612</td><td>$3,731</td></tr><tr><td>Working capital</td><td>1,917</td><td>3,631</td><td>4,492</td></tr><tr><td>Debt, net of cash and cash equivalents</td><td>831</td><td>392</td><td>-1,434</td></tr><tr><td>Debt to capital ratio<sup>-1</sup></td><td>36.8%</td><td>35.7%</td><td>23.4%</td></tr><tr><td>Net debt to net capital employed<sup>-2</sup></td><td>10.8%</td><td>5.1%</td><td>-23.5%</td></tr><tr><td>Return on stockholders’ equity<sup>-3</sup></td><td>19.7%</td><td>16.9%</td><td>18.7%</td></tr></table>
<table><tr><td> <i>(Dollars in billions)</i> </td><td colspan="2"> 2012</td><td colspan="2"> 2011</td><td colspan="2"> 2010</td></tr><tr><td>Distribution Solutions</td><td>$119.4</td><td>97%</td><td>$108.9</td><td>97%</td><td>$105.6</td><td>97%</td></tr><tr><td>Technology Solutions</td><td>3.3</td><td>3%</td><td>3.2</td><td>3%</td><td>3.1</td><td>3%</td></tr><tr><td>Total</td><td>$122.7</td><td>100%</td><td>$112.1</td><td>100%</td><td>$108.7</td><td>100%</td></tr></table>

Question: In the year with largest amount of Corporate, what's the increasing rate of Technology Solutions? (in %)